Adenocarcinoma of the Rectum
Conditions
Keywords
rectal cancer, chemotherapy, chemoradiation
Brief summary
This study combines midostaurin (PKC412) with radiation and a standard chemotherapy drug call 5-Fluorouracil (5-FU) for subjects with advanced rectal cancer. Midostaurin is a type of kinase inhibitor which works by blocking proteins associated with cancer cell growth. Previous studies also suggest that midostaurin may help increase the effectiveness of radiation therapy. In this research we are looking for the highest dose of midostaurin that can be given safely in combination with standard chemoradiation.
Detailed description
Midostaurin capsules will be taken by mouth for 8 weeks. For the first 2 weeks midostaurin will be taken alone (no chemoradiation). After 2 weeks standard chemoradiation will be added to the midostaurin regimen. Subjects receive midostaurin and chemoradiation for an additional 6 weeks. Physical exams will be done weekly. Blood samples will be taken and an optional tumor biopsy will be performed in week 2. 4-5 weeks after completing chemoradiation and midostaurin subjects will undergo surgery as standard of care. Tumor tissue from the surgery will be used for research purposes. A Ct scan of chest, abdomen, and pelvis will be performed. After completion of surgery, subjects will have an end of study visit with physical exam, blood tests. CT scans of chest, abdomen, and pelvis will be performed yearly for 5 years.
Interventions
DRUGMidostaurin
50 mg BID for 8 cycles
Sponsors
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adenocarcinoma of the rectum * T3/4 or N+ disease * Life expectancy \> 3 months * Normal organ and marrow function
Exclusion criteria
* Metastatic disease * Pregnant or breastfeeding * Prior radiotherapy * Receiving other investigational agents * History of inflammatory bowel disease * Active scleroderma or CREST syndrome * Uncontrolled intercurrent illness * History of a different malignancy unless disease free for at least 5 years * HIV or active viral hepatitis * Impaired cardiac function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation | 1.5 years |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation | 1.5 years |
| To determine the rate of Dworak Tumor Regression Grade 3/4 for locally advanced rectal cancer treated with study combination at the MTD, stratified by KRAS status (mutant vs. wild type) | 1.5 years |
| To determine surgical complication rate in patients who received preoperative radiation therapy | 1.5 years |
| Perform an exploratory analysis of the impact of selected mutations in APC, PTEN, BRAF, NRAS, and PIK3CA, among other genes | 1.5 year |
Countries
United States
Outcome results
None listed